AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poole, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poole, K.

Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2233-2241, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

MINIREVIEW

Efflux-Mediated Resistance to Fluoroquinolones in Gram-Negative Bacteria

Keith Poole*

Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada K7L 3N6


    INTRODUCTION
Top
Introduction
Conclusion
References

The introduction of the fluoroquinolones (FQs) in the 1980s provided clinicians with a class of broad-spectrum agents applicable to a range of gram-negative infections including urinary tract infections, gastrointestinal infections, respiratory tract infections, sexually transmitted diseases, bone and joint infections, and infections of the skin and soft tissue (reviewed in references 10 and 43). Targeted microorganisms include the family Enterobacteriaceae, Haemophilus spp., Neisseria spp., and Moraxella spp., which are highly susceptible to these agents, as well as important nosocomial pathogens such as Pseudomonas aeruginosa and Acinetobacter spp. FQs are less active but still clinically useful against Legionella spp.

Given this broad spectrum of activity, it is unfortunate that resistance to FQs has increased in a number of gram-negative organisms, most notably in P. aeruginosa but in virtually all organisms where FQs have been employed (1, 43). Resistance is due usually to mutations in the genes for the bacterial targets of the FQs (DNA gyrase [GyrA] and topoisomerase IV [ParC]) or to active efflux of the agents via antibiotic efflux pumps (59). This review focuses on efflux mechanisms of FQ resistance, their distribution and clinical significance in gram-negative pathogens, the possible natural function(s) of these, and, finally, the potential therapeutic value of efflux pump inhibitors.


    ANTIBIOTIC EFFLUX

Efflux as a mechanism of antibiotic resistance was first reported in the early 1980s, for tetracycline, by two groups of researchers (11, 85). Since then, efflux-mediated resistance to several antimicrobial agents, including FQs, has been reported in a variety of bacterial species, and a number of efflux determinants have been cloned and sequenced (109) (Table 1). Bacterial antimicrobial efflux transporters have generally been grouped into four superfamilies, primarily on the basis of amino acid sequence homology. These include the major facilitator superfamily (MFS) (108), the ATP-binding cassette family (137), the resistance-nodulation-division (RND) family (97, 121), and the small multidrug resistance (SMR) protein family (110). Recently, a fifth family, referred to as the multidrug and toxic compound extrusion (MATE) family, has been identified (13). Antibiotic efflux pumps fall into the RND, MFS, or MATE groups (Fig. 1) and utilize the energy of the proton motive force to export antibiotics from the cell (97, 108, 109). RND family transporters are unique to gram-negative bacteria and typically work in conjunction with a periplasmic membrane fusion protein (MFP) (26, 121) (also called a periplasmic efflux protein [54]) and an outer membrane protein (97) (also called outer membrane [OM] efflux protein [OEP] [54]). This organization provides for efflux of antibiotics across both membranes of the typical gram-negative organism.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   FQ efflux systems of gram-negative bacteria



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 1.   Schematic demonstrating the organization and operation of antimicrobial efflux pumps of gram-negative bacteria. Although some MFS pumps work in conjunction with MFP and OEP counterparts, FQ efflux via a MFS-MFP-OEP tripartite pump has yet to be demonstrated. Abbreviations: PP, periplasmic space; CM, cytoplasmic membrane.


    FQ EFFLUX IN GRAM-NEGATIVE BACTERIA

FQ resistance attributable to efflux has been reported in a number of gram-negative organisms including Burkholderia cepacia, Campylobacter jejuni, Citrobacter freundii, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, P. aeruginosa, Salmonella enterica serovar Typhimurium, Shigella dysentariae, Stenotrophomonas maltophilia, Vibrio parahaemolyticus, and the anaerobe Bacteroides fragilis (Table 1). In most instances efflux was identified as the resistance mechanism because of an observed increase in FQ accumulation in FQ-resistant strains that was, when examined, compromised upon the addition of an energy inhibitor such as carbonyl cyanide m-chlorophenylhydrazone (CCCP). Unfortunately, a CCCP-promoted increase in FQ accumulation has been observed in the absence of an efflux mechanism (35, 100). As such, demonstration of CCCP-enhanced FQ accumulation in bacterial cells alone is insufficient to support the existence of an FQ efflux mechanism. The demonstration of FQ efflux, directly, or of reduced FQ accumulation in FQ-resistant relative to -susceptible strains is necessary before claims of an efflux mechanism can be made.

An interesting feature of strains expressing efflux-mediated quinolone resistance is their cross-resistance to a number of structurally unrelated antimicrobial agents (6, 15, 16, 18-20, 24, 25, 33, 36, 44, 66, 67, 77, 82, 99, 112, 117, 120, 123, 125, 149). This is due to the broad substrate specificity of the FQ efflux systems, which are capable of accommodating a variety of clinically relevant antimicrobial agents in addition to FQs. As such, FQ use and the attendant development of FQ resistance threatens to increase the incidence of multidrug resistance (MDR) in a number of important human pathogens. This is especially true for an organism like P. aeruginosa, where efflux-mediated resistance to FQs seems to predominate as a mechanism of resistance to these agents (50, 51, 62, 144).

RND-Type Efflux Systems

P. aeruginosa. Organisms with known FQ efflux systems of the MFP-RND-OEP type are highlighted in Table 1. In P. aeruginosa, four FQ-MDR efflux systems have been described to date, although numerous homologues are identifiable in the recently completed genome sequence (http://www.pseudomonas.com). The first to be reported, encoded by the mexAB-oprM operon (39, 69, 114, 115), is expressed constitutively in wild-type cells cultivated under usual laboratory conditions, where it contributes to intrinsic resistance to quinolones and other antibiotics (60, 116, 131). The system is also hyperexpressed in so-called nalB mutants, which display elevated resistance to FQs and a variety of other antimicrobials (60, 82, 83, 116, 117). nalB strains carry mutations in a gene, mexR, which occurs immediately upstream of the efflux operon and encodes a repressor of mexAB-oprM expression (53, 116, 122, 132, 152). MexAB-OprM hyperexpression independent of mutations in mexR and the mexR mexAB-oprM intergenic region have also recently been described (132, 152). Dubbed nalC mutants (132), these presumably carry a mutation in a hitherto unidentified regulator of mexAB-oprM expression. The MexAB-OprM system is also growth phase regulated, its expression increasing in late log phase (30). Thus, this FQ-MDR efflux system is highly regulated in P. aeruginosa.

The MexCD-OprJ (113) and MexEF-OprN (61) systems are apparently not expressed in wild-type cells under normal laboratory conditions (45, 61, 131) but are hyperexpressed in nfxB (42, 83, 113) and nfxC (33, 61, 83) mutants, respectively. NfxB mutants carry mutations in a gene, nfxB (105, 106), which is located upstream of the efflux genes and encodes a repressor of mexCD-oprJ expression (113). Two classes of nfxB mutants have been described, expressing moderate (type A) or high (type B) levels of the efflux system, with resistance levels correlating with efflux gene expression (81). The nature of mutations leading to MexEF-OprN hyperexpression in nfxC strains has yet to be elucidated. MexEF-OprN hyperexpression is, however, dependent upon the mexT gene, which is located upstream of mexEF-oprN and encodes a positive regulator of mexEF-oprN expression (63, 102). Unlike the aforementioned efflux operons, the recently described mexXY system (also called amrA [139]) lacks a linked OM gene (87), reminiscent of the acrAB FQ-MDR efflux operon of E. coli (see below). Still, MexXY appears to utilize the product of the oprM gene as its OM constituent (3, 87), consistent with an earlier observation that OprM is functional in efflux-mediated MDR in the absence of MexAB (151). Given that the OM efflux proteins are not functional in the absence of RND-MFP counterparts (i.e., these pumps operate as tripartite pumps only) (141), this was interpreted as an indication that OprM functioned as the OM efflux component for additional efflux systems (151). Again, this was reminiscent of E. coli, in which the TolC OM component of the AcrAB-TolC FQ-MDR efflux system (see below) also functioned as the OM constituent of several other three-component pumps involved in the export of uncouplers (97), colicin V (46) and hemolysin (138). MexXY-OprM-mediated resistance to FQs has only been demonstrated with the cloned genes in E. coli (87) and P. aeruginosa (3). Thus, it is not clear to what extent the chromosomal mexXY genes promote FQ resistance in P. aeruginosa. Inactivation of chromosomal mexXY enhances the organism's susceptibility to several antibiotics, including aminoglycosides, but not to FQs (3), and FQ or MDR mutants hyperexpressing this system have yet to be described. A gene, mexZ (also called amrR [139]), has been identified upstream of mexXY and apparently encodes a repressor of mexXY (amrAB) expression (3, 139).

These three-component efflux systems include an inner membrane, RND-type presumed drug-proton antiporter (MexB, MexD, MexF, or MexY); a periplasmic link or membrane fusion protein (MexA, MexC, MexE, or MexX); and an OM, presumed channel-forming protein (OprM, OprJ, or OprN). The inner membrane and OM components function in the export of antibiotics across the corresponding membrane, while the MFP apparently couples antibiotic export across both membranes by bringing these export components (or the membranes [147]) into close apposition (76, 97). Although drug-proton antiport has not been demonstrated for the RND pump components of P. aeruginosa, their amino acid sequence homology to a heavy metal-proton antiporter in Alcaligenes eutrophus (Ralstonia eutropha) (95) and an MDR-type drug-proton antiporter in E. coli (147) and their inhibition by uncouplers such as CCCP (69) favor this mechanism of action. The MFP components, though periplasmic, are anchored to the cytoplasmic membrane, probably via the acyl moiety of these presumed lipoproteins. The MexA MFP has, in fact, been shown to be acylated, although this acylation appears to be unnecessary for its activity (142). Channel-forming activity has yet to be demonstrated for the OEP components, which appear to be distinct from the porin class of OM channel-forming proteins (54). Moreover, the OEP components contain so-called lipoprotein boxes, typically sites of acylation in lipoproteins, at their N termini, and indeed, acylation of OprM has been demonstrated (N. Bianco and K. Poole, unpublished data). The observation that tonB mutants are compromised with respect to MexAB-OprM-mediated resistance suggests that OprM, at least, is a "corked" channel whose opening is dependent upon energy and the TonB protein (150).

FQ-MDR clinical isolates of the nalB (53, 152), nfxB (51, 53), and nfxC (34) type have been described, although clinical FQ-resistant strains typically display target site mutations (17, 93, 143). It is unlikely, however, that efflux mechanisms were assessed in many of these strains. Still, a recent report indicates that hyperexpression of MexCD-OprJ or MexEF-OprN is the predominant mechanism of FQ resistance in strains isolated from the lungs of cystic fibrosis patients (52). The presence of both efflux and gyrase or topoisomerase mutations in the same strain has, for example, been reported in a number of clinical strains, particularly those exhibiting high-level FQ resistance (18, 47, 53, 145, 148). Given that high-level FQ resistance is invariably associated with multiple mutations (53), it is likely that efflux is a significant contributing factor in many instances. Interestingly, selection of FQ-resistant strains in vitro at FQ concentrations two to four times the MIC in a recent study yielded efflux mutants in >90% of the cases (62), a trend noted previously for the FQs (50, 51, 144) and distinct from the pattern seen for nalidixic acid-resistant strains (where gyrase mutations predominated) (144). This has obvious implications vis-à-vis FQ selection of MDR strains in vivo.

E. coli and the Enterobacteriaceae. The predominant FQ efflux system of E. coli is encoded by the acrAB-tolC genes (32, 74, 76). The AcrAB proteins are highly homologous to the Mex proteins of P. aeruginosa, while TolC has limited homology to the OEPs of P. aeruginosa. TolC has, however, been shown to form channels in planar lipid bilayer membranes (12), consistent with a role in the export of antibiotics across the OM of E. coli. As with the FQ efflux mechanisms of P. aeruginosa, this system is broadly specific and accommodates a number of clinically relevant antimicrobials in addition to FQs (74). This system is expressed in wild-type cells under normal laboratory growth conditions, where it provides for intrinsic resistance, and its hyperexpression in mutants results in elevated resistance to FQs and other agents (74, 97). A related MDR efflux system, encoded by the acrEF (76) (previously called envCD [58]) genes is not expressed in wild-type cells (76) but does accommodate the same antibiotics, including FQs, as does AcrAB (J. Hwang and H. Nikaido, personal communication). Acylation of EnvC-AcrE has been demonstrated (127) although this does not appear to be essential for the function of the MFPs (146). Homologues of these systems have been described in both S. enterica serovar Typhimurium (37, 65, 99) and Haemophilus influenzae (123), although an OM constituent has yet to be confirmed. While the S. enterica serovar Typhimurium counterpart has a demonstrated role in efflux and FQ resistance (99), the H. influenzae AcrAB homologue does not (123). Still, the latter organism possesses an OM of comparatively high permeability (124), and it is known that the OM barrier is an important determinant of resistance mediated by FQ-MDR efflux systems (i.e., they function synergistically) (41, 76, 98). Despite the presence of highly homologous FQ-MDR efflux systems in P. aeruginosa (MexAB-OprM) and E. coli (AcrAB-TolC), for example, the former provides resistance to a broader range of compounds, in particular small hydrophilic antibiotics (131). Moreover, expression of MexAB-OprM in E. coli affords resistance to a narrower range of antibiotics than it does in P. aeruginosa (130). This is apparently because the OM of E. coli is more permeable to these agents than is P. aeruginosa's (96), and their rate of influx, then, is sufficient to overcome the effects of efflux (76). Similarly, disruption of the OM in P. aeruginosa compromises antibiotic resistance mediated by the MexAB-OprM pump (70a, 98). Thus, while the AcrAB system of H. influenzae may well pump FQs, the rather permeable OM of this organism (i.e., enhanced influx) would likely, as H. Nikaido has stated (123), negate this effect. In this vein, Neisseria gonorrhoeae also possesses a homologue of the AcrAB-MexAB FQ-MDR efflux systems, MtrCDE (40), that functions as an antibiotic efflux system but does not provide resistance to FQs. Again, the OM of this organism is apparently more permeable than that of E. coli (and P. aeruginosa) (123).

Expression of acrAB is governed primarily by AcrR, the product of a repressor gene located immediately adjacent to the efflux genes (73), and MarA, a positive regulator encoded by the marA gene of the marRAB operon (4). AcrR is a member of a family of repressor proteins that includes AcrS, which apparently regulates acrEF expression (76), and MtrR, which regulates mtrCDE expression (40). Mutations in acrR (73) or mtrR (40) produce modest increases in efflux gene expression and, thus, modest increases in resistance to substrate antibiotics. The marRAB operon, the so-called mar locus, has long been known to be the site of mutations in E. coli that produce a multiple antibiotic resistance (Mar) phenotype (4). The marR gene encodes a repressor of marRAB expression (and is the site of mutation in most mar strains [4]), while the marA gene product activates a variety of genes associated with resistance to antibiotics and oxygen stress (4). Still, the predominant locus responsible for the MDR of mar mutants is acrAB. This was aptly demonstrated by observations that expression of acrAB is increased in marR mutants (which show elevated marA expression) (75) and the multiple antibiotic resistance of marR mutants is compromised in strains with acrAB deletions (107). Moreover, the cloned marA gene enhances expression of both acrA and tolC (9). Two additional genes, robA and soxS, also increase acrA and tolC expression (9), highlighting the complexity of acrAB-tolC regulation in E. coli. Recently, a null mutation in the mppA gene encoding a periplasmic murein peptide-binding protein was shown to increase MarA production and, concomitantly, the antibiotic resistance of E. coli (68). Still, the mechanism by which MppA influences marA expression remains to be elucidated.

Intriguingly, MarA homologues have been identified in several bacteria, including serovar Typhimurium (21, 133), Shigella spp., Klebsiella spp., C. freundii, Hafnia alvei, Enterobacter spp. (21) and P. vulgaris (48), with marA expression associated with a mar phenotype in Enterobacter agglomerans and S. typhimurium (21). A Mar phenotype has also been reported in P. aeruginosa (148), although a mar locus has yet to be identified in this organism. It is possible, therefore, that these organisms possess FQ-MDR transporters of the AcrAB type. The observation that FQ resistance is increased in K. pneumoniae upon exposure to salicylate (27), a known inducer of the mar operon (23), also suggests that this organism possesses an AcrAB-type efflux system.

The clinical relevance of AcrAB-mediated resistance to FQs or any antibiotic is unclear, although the presence of mar mutations in clinical FQ-resistant strains (78, 104) and the observation that mar mutants are less sensitive to the bactericidal effects of FQs (38) and mutate more readily to high-level FQ resistance (4) suggest it may be important. Moreover, clinical strains of E. coli resistant to FQs and exhibiting decreased accumulation of ciprofloxacin have been described, many of which show very marked increases in ciprofloxacin accumulation upon treatment with CCCP (31). These strains also carry mutations in gyrA and parC, indicating, again, that FQ resistance often results from a combination of efflux and target site mutations (see also reference 56).

Burkholderia spp. First identified as a determinant of chloramphenicol resistance in a clinical strain (15), the ceoAB-opcM operon (GenBank accession number U97042) of B. cepacia encodes an MDR efflux pump which accommodates and, thus, provides resistance to FQs (16; J. L. Burns, C. Ptritzlaff, J. Barry, M. Charon, and M. Cieri, Abstr. 98th Gen. Meet. Am. Soc. Microbiol., abstr. V-108, 1998). Associated with the MDR of a clinical strain, it is unclear if this homologue of the RND-MFP-OEP efflux systems of P. aeruginosa is only expressed in mutant strains (like the nfxB and nfxC mutants of P. aeruginosa) or is expressed constitutively and, thus, contributes to the well-known intrinsic resistance of this organism to many antibiotics. A regulatory gene has not been reported for this efflux system, although salicylate induction of FQ-MDR in B. cepacia (14) is suggestive of a mar locus in this organism (see below). An RND-MFP-OEP homologue, AmrAB-OprA, has recently been described in Burkholderia pseudomallei (91). Also an MDR transporter, this system exports and provides resistance to aminoglycosides and macrolides but not FQs.

S. maltophilia. FQ selection of MDR strains of S. maltophilia (then called Xanthamonas maltophilia), reminiscent of FQ selection of efflux mutants in P. aeruginosa (see above), has been seen, although an efflux mechanism was not originally implicated (66). More recently, FQ-MDR strains have been described which appear to possess efflux mechanisms responsible for the FQ-MDR (6, 149). Of significance, several clinical MDR strains of S. maltophilia expressing homologues of the MexAB-OprM efflux system of P. aeruginosa have been reported (149). In fact, a MexAB-OprM-like efflux system, encoded by the smeABC operon (GenBank accession number AF173226), has been discovered recently in this organism and shown to accommodate FQs as well as other antibiotics (X.-Z. Li, L. Zhang, and K. Poole, unpublished data).

Genome projects. Homologues of the RND-MFP-type MDR systems with and without linked OEP genes are identifiable in the genomes of many bacteria, including Rickettsia prowazekii (7) and Helicobacter pylori (5, 136), where a hefABC operon has been identified by Bina and Hancock (accession number AF059041); as well as the cyanobacterium Synechocystis sp. (55) and Rhodobacter capsulatus (64). BLAST searching of the unfinished genome sequences available on-line (http://www.ncbi.nlm.nih.gov/BLAST/unfinishedgenome.html) also revealed numerous homologues in S. enterica serovar Typhi (four), Bordetella pertussis (four), Yersinia pestis (five), C. jejuni (one), and Vibrio cholerae (two). Whether any of these function in antibiotic efflux remains to be determined. Still, the possibility exists, at least, that FQ-MDR efflux systems are widespread in gram-negative bacteria, where they may play a significant role in resistance to this important class of antibiotic.

MFS- and MATE-Type Efflux Systems

The most common example of an MFS antibiotic efflux system in gram-negative bacteria is that encoded by the various tet genes associated with tetracycline efflux and resistance (119). Members of this family that efflux FQs are, in contrast, rare in gram-negative bacteria, including only the MdfA transporter of E. coli (28), although it appears to be a more effective pump for nonantibiotics. Originally described as MFS transporters, the NorM pump of V. parahaemolyticus (92) and its E. coli homologue YdhE (92) now appear to be members of the newly reported MATE family of transporters (13). These pumps facilitate resistance to multiple agents, including antibiotics and nonantibiotics, and appear to be better exporters of FQs than is MdfA. In the case of all three of the aforementioned transporters, however, efflux and antibiotic resistance were assessed using genes cloned on plasmids and expressed in E. coli. Thus, the relevance of the chromosomal counterparts to FQ resistance is uncertain. As with MFS-type exporters involved in FQ resistance in gram-positive bacteria FQ resistance attributable to NorM and YdhE is limited to the more hydrophilic FQs such as ciprofloxacin and norfloxacin (92).


    FQ EFFLUX SYSTEMS EXHIBIT BROAD SUBSTRATE SPECIFICITY

The most striking feature of the RND-MFP-OEP MDR efflux systems of gram-negative bacteria is their incredibly broad substrate specificity, encompassing a variety of structurally unrelated antimicrobial agents, including clinically relevant antibiotics, dyes (28, 40, 74, 88, 92, 101, 123, 134), detergents (40, 74, 130, 135), disinfectants (84, 89), antimicrobial peptides (129), organic solvents (8, 57, 70, 71, 140), inhibitors of fatty acid synthesis (126), and homoserine lactones involved in bacterial cell-to-cell signalling (29, 111). The binding of multiple structurally varied substrates is uncommon in biology, and how this is achieved in gram-negative FQ-MDR transporters is as yet unknown. This broad substrate specificity contrasts with other examples of antibiotic efflux systems, which tend to be agent or class specific (e.g., the tetracycline [tet] [119] efflux systems). Interestingly, too, the FQ-MDR efflux systems are invariably chromosomally encoded and conserved in both sensitive and resistant strains, with resistance usually resulting from mutational upregulation of the efflux genes. The recently described plasmid-borne FQ resistance determinant (80) appears not to involve efflux, although the mechanism of resistance has yet to be elucidated (G. A. Jacoby, personal communication). Again, this contrasts with the tetracycline efflux systems, which are generally plasmid-borne or transposon-encoded (119). This suggests that FQ-MDR efflux systems are an intrinsic part of the gram-negative bacterium and function independently of antibiotic efflux and resistance, while the others function uniquely in antibiotic efflux and resistance and their acquisition from outside sources provides for antibiotic resistance.


    NATURAL FUNCTION OF FQ-MDR EFFLUX SYSTEMS

The natural role of FQ-MDR efflux systems is the subject of some debate, with support for export of and, thus, protection from exogenous antimicrobial agents available in some instances. The inducibility of the E. coli AcrAB system by toxic fatty acids (75) and the demonstrated role of AcrAB in the export of and resistance to bile salts (135) are consistent with a role for AcrAB in protecting the cell from the action of these agents in the gut (75). A protective function is also likely attributable to the MtrCDE system, which provides for resistance to fecal lipids in rectal isolates of N. gonorrhoeae (128) and, probably, bile salts known to bathe mucous membranes (40). Still, in none of these cases are antibiotics the intended substrate. The fact, too, that most pump genes have linked regulatory genes indicates that the efflux systems are highly regulated and, thus, likely respond to something environmental or cell associated. Although some cell-derived compounds have been identified as substrates for these efflux systems, including homoserine lactone autoinducers in P. aeruginosa (MexAB-OprM) (29, 111) and indole (a precursor of tryptophan) in E. coli (AcrEF) (K. Sato, K. Shibayama, T. Horii, Y. Arakawa, and M. Ohta, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. C-126, 1998), it is far from clear that these are the intended substrates. MexEF-OprN expression in P. aeruginosa, for example, is associated with a decrease in pyocyanin production (61), a phenotype also seen in nalB strains and attributed to homoserine lactone efflux by MexAB-OprM (29). Thus, homoserine lactones may be just another in a line of shared substrates for these highly accommodating MDR efflux systems in P. aeruginosa (K. Sato et al. 38th ICAAC).


    THERAPEUTIC VALUE OF EFFLUX PUMP INHIBITORS

Given the contribution of FQ-MDR efflux systems to low- and high-level FQ resistance in clinical strains of a variety of important human pathogens, it seems logical that they be targets for therapeutic intervention. Indeed, a variety of genetic and inhibitor studies have confirmed the usefulness of pump inactivation in increasing bacterial susceptibility to FQs (and other antibiotics) and preventing emergence of FQ resistance. Mutants of P. aeruginosa with deletions of the genes coding for the three best-characterized FQ-MDR efflux systems of this organism were markedly FQ hypersusceptible, and FQ-resistant derivatives of this deletion strain could not be selected in vitro at clinically relevant concentrations of FQ (72). Moreover, elimination of the FQ-MDR efflux systems in this organism compromised resistance mediated by gyrA mutations (72; K. Poole, unpublished data). Similarly, loss of acrAB in E. coli rendered topoisomerase mutations generally inconsequential as regards clinical FQ resistance (103). Recently, the first examples of broad-spectrum efflux pump inhibitors of the Mex efflux system of P. aeruginosa have been reported (118; O. Lomovskaya, K. Hoshino, H. Ishida, A. Lee, M. Warren, and J. Galazzo, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1264, 1999). These potentiate the activity of a number of antibiotics, including FQs, in vitro (118; Lomovskaya et al., 39th ICAAC) and in animal models of P. aeruginosa infection (D. Griffith, O. Lomovskaya, V. Lee, and M. Dudley, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1268, 1999) and appear also to work in a variety of other gram-negative pathogens (J. Blais, D. Cho, K. Tangen, C. Ford, A. Lee, O. Lomovskaya, and S. Chamberland, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-1266, 1999). These inhibitors were effective at reversing acquired FQ resistance attributable to efflux or target site mutations (Lomovskaya et al., 39th ICAAC). Moreover, these inhibitors markedly decreased the frequency with which highly FQ-resistant strains could be selected in vitro (Lomovskaya et al., 39th ICAAC).


    CONCLUSIONS
Top
Introduction
Conclusion
References

Efflux mechanisms of FQ resistance are widely distributed among important gram-negative human pathogens, where they appear to be components of the normal genetic complement of these bacteria. The identification, too, of several homologues of the RND-MFP-OEP-type efflux systems in the genome sequences of a number of these organisms, in which efflux-mediated FQ resistance has yet to be studied, suggests that the potential for efflux to contribute to FQ resistance is particularly great in gram-negative bacteria. Although there is much debate and uncertainty regarding the natural function of these plentiful FQ-MDR efflux systems, it is clear that they are important contributors to intrinsic and acquired FQ resistance. Inhibition of efflux systems would seem, therefore, a prudent approach to combating and/or preventing FQ resistance. Given the high degree homology of these efflux systems, it should be possible to identify broad-spectrum inhibitors, and indeed, preliminary work with P. aeruginosa efflux pump inhibitors seems to bear this out.


    ACKNOWLEDGMENTS

Work on FQ/MDR efflux systems carried out in the author's laboratory was generously supported by the Canadian Cystic Fibrosis Foundation (CCFF) and the Canadian Bacterial Diseases Network, one of the Networks of Centers of Excellence. K.P. is a CCFF Martha Morton Scholar.

I thank R. Srikumar and G. McKay for critically reading the manuscript.


    ADDENDUM IN PROOF

Recently, the crystal structure of the TolC OM channel of the AcrAB-TolC efflux system of E. coli was reported (V. Koronakis, A. Sharff, E. Koronakis, B. Luisi, and C. Hughes, Nature 405:914-919, 2000). Also, channel-forming activity has now been demonstrated for the OprM component of the MexAB-OprM efflux system of P. aeruginosa (K. K. Y. Wong and R. E. W. Hancock, J. Bacteriol. 182:2402-2410, 2000), although the observed channel size is less than what would be needed to accommodate the various known substrates of this efflux system. Thus, it is still likely that TonB is necessary to mediate channel opening.


    FOOTNOTES

* Mailing address: Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada K7L 3N6. Phone: (613) 533-6677. Fax: (613) 533-6796. E-mail: poolek{at}post.queensu.ca.


    REFERENCES
Top
Introduction
Conclusion
References

1. Acar, J. F. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl. 1):S67-73.
2. Ahamed, J., J. Gangopadhyay, and M. Kundu. 1999. Mechanisms of quinolone resistance in clinical isolates of Shigella dysenteriae. Antimicrob. Agents Chemother. 43:2333-2334[Free Full Text].
3. Aires, J. R., T. Köhler, H. Nikaido, and P. Plésiat. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628[Abstract/Free Full Text].
4. Alekshun, M. N., and S. B. Levy. 1999. The mar regulon: multiple resistance to antibiotics and other toxic chemicals. Trends Microbiol. 7:410-413[CrossRef][Medline].
5. Alm, R. A., L. S. Ling, D. T. Moir, B. L. King, E. D. Brown, P. C. Doig, D. R. Smith, B. Noonan, B. C. Guild, B. L. deJonge, G. Carmel, P. J. Tummino, A. Caruso, M. Uria-Nickelsen, D. M. Mills, C. Ives, R. Gibson, D. Merberg, S. D. Mills, Q. Jiang, D. E. Taylor, G. F. Vovis, and T. J. Trust. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397:176-180[CrossRef][Medline].
6. Alonso, A., and J. L. Martinez. 1997. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1140-1142[Abstract].
7. Andersson, S. G., A. Zomorodipour, J. O. Andersson, T. Sicheritz-Ponten, U. C. Alsmark, R. M. Podowski, A. K. Naslund, A. S. Eriksson, H. H. Winkler, and C. G. Kurland. 1998. The genome sequence of Rickettsia prowazekii and the origin of mitochondria. Nature 396:133-140[CrossRef][Medline].
8. Aono, R. 1998. Improvement of organic solvent tolerance level of Escherichia coli by overexpression of stress-responsive genes. Extremophiles 2:239-248[CrossRef][Medline].
9. Aono, R., N. Tsukagoshi, and M. Yamamoto. 1998. Involvement of outer membrane protein TolC, a possible member of the mar-sox regulon, in maintenance and improvement of organic solvent tolerance of Escherichia coli K-12. J. Bacteriol. 180:938-944[Abstract/Free Full Text].
10. Ball, P. 1998. The quinolones: history and overview, p. 1-28. In V. T. Andriole (ed.), The quinolones, 2nd ed. Academic Press, San Diego, Calif.
11. Ball, P. R., S. W. Shales, and I. Chopra. 1980. Plasmid-mediated tetracycline resistance in Escherichia coli involves increased efflux of the antibiotic. Biochem. Biophys. Res. Commun. 93:74-81[CrossRef][Medline].
12. Benz, R., E. Maier, and I. Gentshev. 1993. TolC of Escherichia coli functions as an outer membrane channel. J. Bacteriol. 178:5803-5805[Abstract/Free Full Text].
13. Brown, M. H., I. T. Paulsen, and R. A. Skurray. 1999. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol. Microbiol. 31:393-395[CrossRef][Medline].
14. Burns, J. L., and D. K. Clark. 1992. Salicylate-inducible antibiotic resistance in Pseudomonas cepacia associated with absence of a pore-forming outer membrane protein. Antimicrob. Agents Chemother. 36:2280-2285[Abstract/Free Full Text].
15. Burns, J. L., L. A. Hedin, and D. M. Lien. 1989. Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability. Antimicrob. Agents Chemother. 33:136-141[Abstract/Free Full Text].
16. Burns, J. L., C. D. Wadsworth, J. J. Barry, and C. P. Goodall. 1996. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob. Agents Chemother. 40:307-313[Abstract].
17. Cambau, E., E. Perani, C. Dib, C. Petinon, J. Trias, and V. Jarlier. 1995. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem. Antimicrob. Agents Chemother. 39:2248-2252[Abstract].
18. Celesk, R. A., and R. A. Robillard. 1989. Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 33:1921-1926[Abstract/Free Full Text].
19. Chamberland, S., A. S. Bayer, T. Schollaardt, S. A. Wong, and L. E. Bryan. 1989. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob. Agents Chemother. 33:624-634[Abstract/Free Full Text].
20. Charvalos, E., Y. Tselentis, M. Michea Hamzehpour, T. Koehler, and J.-C. Pechere. 1995. Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Antimicrob. Agents Chemother. 39:2019-2022[Abstract].
21. Cohen, S. H., W. Yan, and S. B. Levy. 1993. A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria. J. Infect. Dis. 168:484-488[Medline].
22. Cohen, S. P., D. C. Hooper, J. S. Wolfson, K. S. Souza, L. M. McMurry, and S. B. Levy. 1988. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob. Agents Chemother. 32:1187-1191[Abstract/Free Full Text].
23. Cohen, S. P., S. B. Levy, J. Foulds, and J. L. Rosner. 1993. Salicylate induction of antibiotic resistance in Escherichia coli: activation of the mar operon and a mar-independent pathway. J. Bacteriol. 175:7856-7862[Abstract/Free Full Text].
24. Cohen, S. P., L. M. McMurry, D. C. Hooper, J. S. Wolfson, and S. B. Levy. 1989. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistance (Mar) Escherichia coli selected by tetracycline resistance: decreased drug accumulation asociated with membrane changes in addition to OmpF reduction. Antimicrob. Agents Chemother. 33:1318-1325[Abstract/Free Full Text].
25. Deguchi, T., T. Kawamura, M. Yasuda, M. Nakano, H. Fukuda, H. Kato, N. Kato, Y. Okanao, and Y. Kawada. 1997. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Antimicrob. Agents Chemother. 41:1609-1611[Abstract].
26. Dinh, T., I. T. Paulsen, and M. H. Saier, Jr. 1994. A family of extracytoplasmic proteins that allow transport of large molecules across the outer membranes of gram-negative bacteria. J. Bacteriol. 176:3825-3831[Abstract/Free Full Text].
27. Domenico, P., T. Hopkins, and B. A. Cunha. 1990. The effect of sodium salicylate on antibiotic susceptibility and synergy in Klebsiella pneumoniae. J. Antimicrob. Chemother. 26:343-351[Abstract/Free Full Text].
28. Edgar, R., and E. Bibi. 1997. MdfA, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179:2274-2280[Abstract/Free Full Text].
29. Evans, K., L. Passador, R. Srikumar, E. Tsang, J. Nezezon, and K. Poole. 1998. Influence of the MexAB-OprM multidrug efflux system on quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 180:5443-5447[Abstract/Free Full Text].
30. Evans, K., and K. Poole. 1999. The MexA-MexB-OprM multidrug efflux system of Pseudomonas aeruginosa is growth-phase regulated. FEMS Microbiol. Lett. 173:35-39[CrossRef][Medline].
31. Everett, M. J., Y. F. Jin, V. Ricci, and L. J. Piddock. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386[Abstract].
32. Fralick, J. A. 1996. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J. Bacteriol. 178:5803-5805.
33. Fukuda, H., M. Hosaka, K. Hirai, and S. Iyobe. 1990. New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob. Agents Chemother. 34:1757-1761[Abstract/Free Full Text].
34. Fukuda, H., M. Hosaka, S. Iyobe, N. Gotoh, T. Nishino, and K. Hirai. 1995. nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:790-792[Abstract].
35. Furet, Y. X., J. Deshusses, and J. C. Pechere. 1992. Transport of pefloxacin across the bacterial cytoplasmic membrane in quinolone-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 36:2506-2511[Abstract/Free Full Text].
36. Ghosh, A. S., J. Ahamed, K. K. Chauhan, and M. Kundu. 1998. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem. Biophys. Res. Commun. 242:54-56[CrossRef][Medline].
37. Giraud, E., A. Cloeckaert, D. Kerboeuf, and E. Chaslus-Dancla. 2000. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44:1223-1228[Abstract/Free Full Text].
38. Goldman, J. D., D. G. White, and S. B. Levy. 1996. Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. Antimicrob. Agents Chemother. 40:1266-1269[Abstract].
39. Gotoh, N., H. Tsujimoto, K. Poole, J.-I. Yamagishi, and T. Nishino. 1995. The outer membrane protein OprM of Pseudomonas aeruginosa is encoded by oprK of the mexA-mexB-oprK multidrug resistance operon. Antimicrob. Agents Chemother. 39:2567-2569[Abstract].
40. Hagman, K. E., W. Pan, B. G. Spratt, J. T. Balthazar, R. C. Judd, and W. M. Shafer. 1995. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 141:611-622[Abstract].
41. Hancock, R. E. W. 1997. The bacterial outer membrane as a drug barrier. Trends Microbiol. 5:37-42[CrossRef][Medline].
42. Hirai, K., S. Suzue, T. Irikura, S. Iyobe, and S. Mitsuhashi. 1987. Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31:582-586[Abstract/Free Full Text].
43. Hooper, D. C. 1998. Clinical applications of quinolones. Biochim. Biophys. Acta 1400:45-61[Medline].
44. Hooper, D. C., J. S. Wolfson, K. S. Souza, E. Y. Ng, G. L. McHugh, and M. N. Swartz. 1989. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob. Agents Chemother. 33:283-290[Abstract/Free Full Text].
45. Hosaka, M., N. Gotoh, and T. Nishino. 1995. Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ. Antimicrob. Agents Chemother. 39:1731-1735[Abstract].
46. Hwang, J., X. Zhong, and P. C. Tai. 1997. Interactions of dedicated export membrane proteins of the colicin V secretion system: CvaA, a member of the membrane fusion protein family, interacts with CvaB and TolC. J. Bacteriol. 179:6264-6270[Abstract/Free Full Text].
47. Irikura, T., S. Iyobe, and S. Mitsuhashi. 1989. New quinolone resistance in clinical isolates of Pseudomonas aeruginosa. Rev. Infect. Dis. 11(Suppl. 5):S972-973.
48. Ishida, H., H. Fuziwara, Y. Kaibori, T. Horiuchi, K. Sato, and Y. Osada. 1995. Cloning of multidrug resistance gene pqrA from Proteus vulgaris. Antimicrob. Agents Chemother. 39:453-457[Abstract/Free Full Text].
49. Ishii, H., K. Sato, K. Hoshino, M. Sato, A. Yamaguchi, T. Sawai, and Y. Osada. 1991. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris. J. Antimicrob. Chemother. 28:827-836[Abstract/Free Full Text].
50. Iyobe, S., K. Hirai, and H. Hashimoto. 1991. Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones. Chemotherapy (Basel) 44:209-214.
51. Jakics, E. B., S. Iyobe, K. Hirai, H. Fukuda, and H. Hashimoto. 1992. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:2562-2565[Abstract/Free Full Text].
52. Jalal, S., O. Ciofu, N. Hoiby, N. Gotoh, and B. Wretlind. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis. Antimicrob. Agents Chemother. 44:710-712[Abstract/Free Full Text].
53. Jalal, S., and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microbiol. Drug Resist. 4:257-261.
54. Johnson, J. M., and G. M. Church. 1999. Alignment and structure prediction of divergent protein families: periplasmic and outer membrane proteins of bacterial efflux pumps. J. Mol. Biol. 287:695-715[CrossRef][Medline].
55. Kaneko, T., S. Sato, H. Kotani, A. Tanaka, E. Asamizu, Y. Nakamura, N. Miyajima, M. Hirosawa, M. Sugiura, S. Sasamoto, T. Kimura, T. Hosouchi, A. Matsuno, A. Muraki, N. Nakazaki, K. Naruo, S. Okumura, S. Shimpo, C. Takeuchi, T. Wada, A. Watanabe, M. Yamada, M. Yasuda, and S. Tabata. 1996. Sequence analysis of the genome of the unicellular cyanobacterium Synechocystis sp. strain PCC6803. II. Sequence determination of the entire genome and assignment of potential protein-coding regions. DNA Res. 3:109-136[Abstract].
56. Kern, W. V., M. Oethinger, A. S. Jellen-Ritter, and S. B. Levy. 2000. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44:814-820[Abstract/Free Full Text].
57. Kieboom, J., J. J. Dennis, G. J. Zylstra, and J. A. de Bont. 1998. Active efflux of organic solvents by Pseudomonas putida S12 is induced by solvents. J. Bacteriol. 180:6769-6772[Abstract/Free Full Text].
58. Klein, J. R., B. Henrich, and R. Plapp. 1991. Molecular analysis and nucleotide sequence of the envCD operon of Escherichia coli. Mol. Gen. Genet. 230:230-240[CrossRef][Medline].
59. Köhler, T., and J.-C. Pechere. 1998. Bacterial resistance to quinolones: mechanisms and clinical implications, p. 117-142. In V. T. Andriole (ed.), The quinolones. Academic Press, London, United Kingdom.
60. Köhler, T., M. Kok, M. Michea-Hamzehpour, P. Plesiat, N. Gotoh, T. Nishino, L. Kocjanici Curty, and J.-C. Pechere. 1996. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:2288-2290[Abstract].
61. Köhler, T., M. Michea-Hamzehpour, U. Henze, N. Gotoh, L. K. Curty, and J.-C. Pechere. 1997. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23:345-354[CrossRef][Medline].
62. Köhler, T., M. Michea-Hamzehpour, P. Plesiat, A.-L. Kahr, and J.-C. Pechere. 1997. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2540-2543[Abstract].
63. Köhler, T., S. F. Epp, L. K. Curty, and J.-C. Pechère. 1999. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J. Bacteriol. 181:6300-6305[Abstract/Free Full Text].
64. Kumar, V., M. Fonstein, and R. Haselkorn. 1996. Bacterium genome sequence. Nature 381:653-654[CrossRef][Medline].
65. Lacroix, F. J. C., A. Cloeckaert, O. Grépinet, C. Pinault, M. Y. Popoff, H. Waxin, and P. Pardon. 1996. Salmonella typhimurium acrB-like gene: identification and role in resistance to biliary salts and detergents and in murine infection. FEMS Microbiol. Lett. 135:161-167[CrossRef][Medline].
66. Lecso-Bornet, M., J. Pierre, D. Sarkis-Karam, S. Lubera, and E. Bergogne-Berezin. 1992. Susceptibility of Xanthamonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob. Agents Chemother. 36:669-671[Abstract/Free Full Text].
67. Legakis, N. J., L. S. Tzouvelekis, A. Makris, and H. Kotsifaki. 1989. Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin. Antimicrob. Agents Chemother. 33:124-127[Abstract/Free Full Text].
68. Li, H., and J. T. Park. 1999. The periplasmic murein peptide-binding protein MppA is a negative regulator of multiple antibiotic resistance in Escherichia coli. J. Bacteriol. 181:4842-4847[Abstract/Free Full Text].
69. Li, X.-Z., H. Nikaido, and K. Poole. 1995. Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1948-1953[Abstract].
70. Li, X.-Z., L. Zhang, and K. Poole. 1998. Role of the multidrug efflux systems of Pseudomonas aeruginosa in organic solvent tolerance. J. Bacteriol. 180:2987-2991[Abstract/Free Full Text].
70a. Li, X.-Z., L. Zhang, and K. Poole. 2000. Interplay between the MexAB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J. Antimicrob. Chemother. 45:433-436[Abstract/Free Full Text].
71. Li, X. Z., and K. Poole. 1999. Organic solvent-tolerant mutants of Pseudomonas aeruginosa display multiple antibiotic resistance. Can. J. Microbiol. 45:18-22[CrossRef][Medline].
72. Lomovskaya, O., A. Lee, K. Hoshino, H. Ishida, A. Mistry, M. S. Warren, E. Boyer, S. Chamberland, and V. J. Lee. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1340-1346[Abstract/Free Full Text].
73. Ma, D., M. Alberti, C. Lynch, H. Nikaido, and J. E. Hearst. 1996. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals. Mol. Microbiol. 19:101-112[CrossRef][Medline].
74. Ma, D., D. N. Cook, M. Alberti, N. G. Pon, H. Nikaido, and J. E. Hearst. 1993. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli. J. Bacteriol. 175:6299-6313[Abstract/Free Full Text].
75. Ma, D., D. N. Cook, M. Alberti, N. G. Pon, H. Nikaido, and J. E. Hearst. 1995. Genes acrA and acrB encode a stress-induced system of Escherichia coli. Mol. Microbiol. 16:45-55[CrossRef][Medline].
76. Ma, D., D. N. Cook, J. E. Hearst, and H. Nikaido. 1994. Efflux pumps and drug resistance in Gram-negative bacteria. Trends Microbiol. 2:489-493[CrossRef][Medline].
77. Mallea, M., J. Chevalier, C. Bornet, A. Eyraud, A. Davin-Regli, C. Bollet, and J.-M. Pagès. 1998. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 144:3003-3009[Abstract].
78. Maneewannakul, K., and S. B. Levy. 1996. Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:1695-1698[Abstract].
79. Martínez-Martínez, L., I. García, S. Ballesta, V. J. Benedí, S. Hernández-Allés, and A. Pascual. 1998. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob. Agents Chemother. 42:1850-1852[Abstract/Free Full Text].
80. Martínez-Martínez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799[CrossRef][Medline].
81. Masuda, N., N. Gotoh, S. Ohya, and T. Nishino. 1996. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 40:909-913[Abstract].
82. Masuda, N., and S. Ohya. 1992. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:1847-1851[Abstract/Free Full Text].
83. Masuda, N., E. Sakagawa, and S. Ohya. 1995. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:645-649[Abstract].
84. McMurry, L. M., M. Oethinger, and S. B. Levy. 1998. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol. Lett. 166:305-309[CrossRef][Medline].
85. McMurry, L. M., R. E. Petrucci, Jr., and S. B. Levy. 1980. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc. Natl. Acad. Sci. USA 77:3974-3977[Abstract/Free Full Text].
86. Michea-Hamzehpour, M., C. Lucain, and J.-C. Pechere. 1991. Resistance to pefloxacin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 35:512-518[Abstract/Free Full Text].
87. Mine, T., Y. Morita, A. Kataoka, T. Mitzushima, and T. Tsuchiya. 1999. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:415-417[Abstract/Free Full Text].
88. Miyamae, S., H. Nikaido, Y. Tanaka, and F. Yoshimura. 1998. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42:2119-2121[Abstract/Free Full Text].
89. Moken, M. C., L. M. McMurry, and S. B. Levy. 1997. Selection of multiple-antibiotic-resistant (mar) mutants of Escherichia coli by using the disinfectant pine oil: roles of the mar and acrAB loci. Antimicrob. Agents Chemother. 41:2770-2772[Abstract].
90. Moniot-Ville, N., J. G. Moreau, J. F. Acar, E. Collatz, and L. Gutmann. 1991. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob. Agents Chemother. 35:519-523[Abstract/Free Full Text].
91. Moore, R. A., D. DeShazer, S. Reckseidler, A. Weissman, and D. E. Woods. 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43:465-470[Abstract/Free Full Text].
92. Morita, Y., K. Kodama, S. Shiota, T. Mine, A. Kataoka, T. Mizushima, and T. Tsuchiya. 1998. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents Chemother. 42:1778-1782[Abstract/Free Full Text].
93. Mouneimne, H., J. Robert, V. Jarlier, and E. Cambau. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:62-66[Abstract/Free Full Text].
94. Navia, M. M., J. Ruiz, A. Ribera, M. T. de Anta, and J. Vila. 1999. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii. J. Antimicrob. Chemother. 44:743-748[Abstract/Free Full Text].
95. Nies, D. H. 1995. The cobalt, zinc, and cadmium efflux system CzcABC from Alcaligenes eutrophus functions as a cation-proton antiporter in Escherichia coli. J. Bacteriol. 177:2707-2712[Abstract/Free Full Text].
96. Nikaido, H. 1989. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother. 33:1831-1836[Free Full Text].
97. Nikaido, H. 1998. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin. Infect. Dis. 27(Suppl. 1):S32-41.
98. Nikaido, H. 1998. The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access? Drug Res. Update 1:93-98.
99. Nikaido, H., M. Basina, V. Nguyen, and E. Y. Rosenberg. 1998. Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta -lactam antibiotics containing lipophilic side chains. J. Bacteriol. 180:4686-4692[Abstract/Free Full Text].
100. Nikaido, H., and D. G. Thanassi. 1993. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob. Agents Chemother. 37:1393-1399[Free Full Text].
101. Ocaktan, A., H. Yoneyama, and T. Nakae. 1997. Use of fluorescence probes to monitor function of the subunit proteins of the MexA-MexB-OprM drug extrusion machinery in Pseudomonas aeruginosa. J. Biol. Chem. 272:21964-21969[Abstract/Free Full Text].
102. Ochs, M. M., M. P. McCusker, M. Bains, and R. E. Hancock. 1999. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob. Agents Chemother. 43:1085-1090[Abstract/Free Full Text].
103. Oethinger, M., W. V. Kern, A. S. Jellen-Ritter, L. M. McMurry, and S. B. Levy. 2000. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 44:10-13[Abstract/Free Full Text].
104. Oethinger, M., I. Podglajen, W. V. Kern, and S. B. Levy. 1998. Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob. Agents Chemother. 42:2089-2094[Abstract/Free Full Text].
105. Okazaki, T., and K. Hirai. 1992. Cloning and nucleotide sequence of the Pseudomonas aeruginosa nfxB gene, conferring resistance to new quinolones. FEMS Microbiol. Lett. 97:197-202[CrossRef].
106. Okazaki, T., S. Iyobe, H. Hashimoto, and K. Hirai. 1991. Cloning and characterization of a DNA fragment that complements the nfxB mutation in Pseudomonas aeruginosa PAO. FEMS Microbiol. Lett. 79:31-36[CrossRef].
107. Okusu, H., D. Ma, and H. Nikaido. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178:306-308[Abstract/Free Full Text].
108. Pao, S. S., I. T. Paulsen, and M. H. Saier, Jr. 1998. Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 62:1-34[Abstract/Free Full Text].
109. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608[Abstract/Free Full Text].
110. Paulsen, I. T., R. A. Skurray, R. Tam, M. H. Saier, Jr., R. J. Turner, J. H. Weiner, E. B. Goldberg, and L. L. Grinius. 1996. The SMR family: a novel family of multidrug efflux protein involved with the efflux of lipophilic drugs. Mol. Microbiol. 19:1175.
111. Pearson, J. P., C. Van Delden, and B. H. Iglewski. 1999. Active efflux and diffusion are involved in transport of Pseudomonas aeruginosa cell-to-cell signals. J. Bacteriol. 181:1203-1210[Abstract/Free Full Text].
112. Piddock, L. J. V., M. C. Hall, F. Bellido, M. Bains, and R. E. W. Hancock. 1992. A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36:1057-1061[Abstract/Free Full Text].
113. Poole, K., N. Gotoh, H. Tsujimoto, Q. Zhao, A. Wada, T. Yamasaki, S. Neshat, J.-I. Yamagishi, X.-Z. Li, and T. Nishino. 1996. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB multidrug resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21:713-724[CrossRef][Medline].
114. Poole, K., D. E. Heinrichs, and S. Neshat. 1993. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol. Microbiol. 10:529-544[CrossRef][Medline].
115. Poole, K., K. Krebes, C. McNally, and S. Neshat. 1993. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J. Bacteriol. 175:7363-7372[Abstract/Free Full Text].
116. Poole, K., K. Tetro, Q. Zhao, S. Neshat, D. Heinrichs, and N. Bianco. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40:2021-2028[Abstract].
117. Rella, M., and D. Haas. 1982. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta -lactam antibiotics: mapping of chromosomal genes. Antimicrob. Agents Chemother. 22:242-249[Abstract/Free Full Text].
118. Renau, T. E., R. Leger, E. M. Flamme, J. Sangalang, M. W. She, R. Yen, C. L. Gannon, D. Griffith, S. Chamberland, O. Lomovskaya, S. J. Hecker, V. J. Lee, T. Ohta, and K. Nakayama. 1999. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem. 42:4928-4931[CrossRef][Medline].
119. Roberts, M. C. 1996. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol. Lett. 19:1-24.
120. Robillard, R. A., and A. L. Scarpa. 1988. Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO. Antimicrob. Agents Chemother. 32:535-539[Abstract/Free Full Text].
121. Saier, M. H., R. Tam, A. Reizer, and J. Reizer. 1994. Two novel families of bacterial membrane proteins concerned with nodulation, cell division and transport. Mol. Microbiol. 11:841-847[CrossRef][Medline].
122. Saito,